ArticleChemical science2024
Molecular engineering of AIE-active boron clustoluminogens for enhanced boron neutron capture therapy.
Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 53 citations in OpenAlex.
- Stereospecific alkenylation of carboranes: copper-catalyzed access to pyridylcarboranyl alkenes.Chemical science · 2026Article
- Systemic Immunity Triggered by Boron Neutron Capture Therapy via Manganese-Borate Complex.Materials today. Bio · 2026Article
- State-of-the-art boron clusters for boron neutron-capture therapy.Theranostics · 2026Review
- Post-coordination of Ru(ii) controlled regioselective B(4)-H acylmethylation ofChemical science · 2025Article
- Photoresponsive tetracoordinate arylboron smart molecules: Strategies for molecular design and photoresponse mechanisms.Smart molecules : open access · 2024Review
- Couple-close construction of non-classical boron cluster-phosphonium conjugates.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of boron delivery agents bearing an imaging capability is crucial for boron neutron capture therapy (BNCT), yet it has been rarely explored. Here we present a new type of boron delivery agent that integrates aggregation-induced emission (AIE)-active imaging and a carborane cluster for the first time. In doing so, the new boron delivery agents have been rationally designed by incorporating a high boron content unit of a carborane cluster, an erlotinib targeting unit towards lung cancer cells, and a donor-acceptor type AIE unit bearing naphthalimide. The new boron delivery agents demonstrate both excellent AIE properties for imaging purposes and highly selective accumulation in tumors. For example, at a boron delivery agent dose of 15 mg kg
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.